Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176

NCT02544217 is registered in ClinicalTrials.gov with Khondrion BV as lead sponsor.

NCT NCT02544217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02544217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176
Lead sponsor
Khondrion BV
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2015
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leigh syndrome, lhon, melas, mitochondrial disease, mitochondrial dna trnaleu(uur) m.3243a<g mutation